Home › Cancro al seno › Oregon
Studi clinici su Cancro al seno nello stato di Oregon
41 studi su Cancro al seno cercano partecipanti presso sedi nello stato di Oregon.
Città nello stato di Oregon
Testo ufficiale dello studio (inglese)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Oregon Health & Science University (OHSU), Portland
In reclutamentoFase 1/2
Età 12 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT04585750Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Good Samaritan Regional Medical Center, Corvallis
- Oncology Associates of Oregon PC, Eugene
- Northwest Cancer Specialists, Portland
- e altri 1
In reclutamentoFase 3
Età da 18 a 100 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05827081Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Charles Health System, Bend
- Clackamas Radiation Oncology Center, Clackamas
- e altri 7
In reclutamentoStudio osservazionaleVolontari sani benvenuti
Età da 40 a 75 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05334069A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
- Compass Oncology - Rose Quarter Cancer Center, Portland
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT07701941A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Portland
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 set 2026 · NCT05877599Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Portland
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT05867251A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Northwest Cancer Specialists (Compass Oncology) ( Site 8010), Tigard
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06966700A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Providence Portland Medical Center ( Site 0044), Portland
- Providence St. Vincent Medical Center ( Site 0081), Portland
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06312176ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- Oregon Health and Science University, Portland
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07007559A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
- Local Institution - 0052, Portland
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 set 2026 · NCT06618287Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Portland
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 set 2026 · NCT07085767A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Good Samaritan Regional Medical Center, Corvallis
- Oncology Associates of Oregon, Eugene
- Oregon Health and Science University, Portland
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07174336A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
In reclutamentoFase 2
Età 18 e oltre · Donne · Aggiornato il 22 set 2026 · NCT07287098ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- St Charles Bend Cancer Center, Bend
- Providence Portland Medical Center, Portland
- St. Charles Cancer Center - Redmond, Redmond
- e altri 1
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 set 2026 · NCT07173751A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Providence Cancer Institute Franz Clinic, Portland
- Providence Cancer Institute Franz Clinic, Portland
- Oregon Oncology Specialists, Salem
- e altri 1
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 15 set 2026 · NCT06492616Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
- Northwest Cancer Specialists (Compass Oncology) ( Site 8003), Tigard
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 10 set 2026 · NCT06797635Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Providence Portland Medical Center, Portland
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 10 set 2026 · NCT06293898A Phase 1/1b Study of IAM1363 in HER2 Cancers
- Providence Cancer Institute, Portland
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 9 set 2026 · NCT06253871A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- Oncology Associates of Oregon, P.C, Eugene
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 8 set 2026 · NCT07100106Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Oregon Health & Science University, Knight Cancer Institute, Portland
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 3 set 2026 · NCT06982521A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Providence Portland Medical Center, Portland
- Providence Oncology and Hematology Cancer Clinic - Westside;Investigation Drug Services Pharmacy, Portland
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 3 set 2026 · NCT06790693Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Charles Health System, Bend
- Clackamas Radiation Oncology Center, Clackamas
- e altri 10
In reclutamentoFase 3
Età da 18 a 60 · Donne · Aggiornato il 2 set 2026 · NCT05879926A Study of MGC026 in Participants With Advanced Solid Tumors
- Providence Cancer Institute, Portland
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 11 ago 2026 · NCT06242470A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Willamette Valley Cancer Institute, Eugene
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 10 ago 2026 · NCT06926868Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
- Hematology Oncology Associates, Medford
- Compass Oncology - Northwest Cancer Specialists, Tigard
In reclutamentoFase 3
Età da 18 a 100 · Tutti i sessi · Aggiornato il 6 ago 2026 · NCT05232916Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Oncology Associates of Oregon, P.C., Eugene
- Compass Oncology - Rose Quarter, Portland
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 ago 2026 · NCT05579366E-Mindfulness Approaches for Living After Breast Cancer
- Saint Charles Health System, Bend
- Providence Hood River Memorial Hospital, Hood River
- Providence Newberg Medical Center, Newberg
- e altri 6
In reclutamentoFase 3
Età da 18 a 50 · Tutti i sessi · Aggiornato il 4 ago 2026 · NCT06748222Virtual Mindful After Cancer (MAC) Intervention to Promote Sexual Health for Breast and Gynecologic Cancer Survivors
- Samaritan Pastega Regional Cancer Center, Corvallis
In reclutamentoFase 1
Età 18 e oltre · Donne · Aggiornato il 17 lug 2026 · NCT07055854Identifying and Caring for Individuals With Inherited Cancer Syndrome
- Providence Portland Medical Center, Portland
- OHSU Knight Cancer Institute, Portland
In reclutamentoVolontari sani benvenuti
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 lug 2026 · NCT04494945First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Providence Cancer Institute Franz Clinic, Portland
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 7 lug 2026 · NCT05768139Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
- Oncology Associates of Oregon, Springfield
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 lug 2026 · NCT07558733177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
- OHSU Knight Cancer Institute, Portland
In reclutamentoFase 2
Età da 18 a 100 · Tutti i sessi · Aggiornato il 5 giu 2026 · NCT04529044I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Oregon Health & Science Institute (OHSU), Portland
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 6 mag 2026 · NCT01042379De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- Clackamas Radiation Oncology Center, Clackamas
- Legacy Mount Hood Medical Center, Gresham
- Providence Newberg Medical Center, Newberg
- e altri 5
In reclutamentoFase 3
Età da 50 a 70 · Tutti i sessi · Aggiornato il 23 apr 2026 · NCT04852887Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Kaiser Permanente Northwest, Portland
In reclutamentoStudio osservazionale
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 mar 2026 · NCT06418204cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Oregon Health Sciences University, Portland
In reclutamentoStudio osservazionaleVolontari sani benvenuti
Età 40 e oltre · Tutti i sessi · Aggiornato il 20 gen 2026 · NCT05366881SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Portland
In reclutamentoStudio osservazionale
Tutte le età · Tutti i sessi · Aggiornato il 28 ott 2025 · NCT03452774S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- Kaiser Permanente Northwest, Portland
- Oregon Health and Science University, Portland
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 8 ott 2025 · NCT03418961MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
- Willamette Valley Cancer Institute and Research Center, Eugene
- Legacy Good Samaritan Medical Center, Portland
In reclutamentoStudio osservazionale
Età 18 e oltre · Tutti i sessi · Aggiornato il 20 ago 2025 · NCT03053193EMBRACE: Exercising Together
- OHSU Knight Cancer Institute, Portland
In reclutamentoFase 2Volontari sani benvenuti
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 mag 2025 · NCT06049355Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.